
Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Key Health Care Changes During Trump’s First Year Back in Office
2
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
3
Maternal Morbidity Increased in States Enacting TRAP Laws
4
Zanidatamab Shows Breakthrough Survival Gains in Metastatic Gastroesophageal Cancer: Elena Elimova, MD
5






























































